Michele Milella
University of Verona
CancerInternal medicineSurgeryOncologyApoptosisLung cancerChemotherapyRenal cell carcinomaPancreatic cancerGemcitabinePopulationIn patientCancer researchBreast cancerClinical trialMAPK/ERK pathwayCell growthMedicinePI3K/AKT/mTOR pathwayBiologyGastroenterology
378Publications
50H-index
9,880Citations
Publications 385
Newest
#1Melissa Frizziero (University of Manchester)
#2Alice DurandH-Index: 2
Last. Sara CingarliniH-Index: 23
view all 0 authors...
Extra-pulmonary neuroendocrine carcinomas (EP-NECs) are lethal cancers with limited treatment options. Identification of contributing factors to the observed heterogeneity of clinical outcomes within the EP-NEC family is warranted, to enable identification of effective treatments. A multicentre retrospective study investigated potential differences in “real-world” treatment/survival outcomes between small-cell (SC) versus (vs.) non-SC EP-NECs. One-hundred and seventy patients were included: 77 (...
Source
#3Alice DurandH-Index: 2
Last. Claudio LuchiniH-Index: 31
view all 0 authors...
view all 0 authors...
Source
#1Giulia Orsi (UniSR: Vita-Salute San Raffaele University)H-Index: 10
#2M. Di Marco (UNIBO: University of Bologna)H-Index: 7
Last. Giampaolo Tortora (UCSC: Catholic University of the Sacred Heart)H-Index: 13
view all 30 authors...
Background null Germline BRCA1-2 pathogenic variants (gBRCA1-2pv)-related pancreatic ductal adenocarcinoma (PDAC) showed increased sensitivity to DNA cross-linking agents. This study aimed at exploring safety profile, dose intensity, and activity of different chemotherapy regimens in this setting. null Patients and methods null gBRCA1-2pv PDAC patients of any age and clinical tumor stage who completed a first course of chemotherapy were eligible. A descriptive analysis of chemotherapy toxicity, ...
Source
#1Raffaella Casolino (Glas.: University of Glasgow)H-Index: 2
#2Andrew V. Biankin (Glas.: University of Glasgow)H-Index: 73
Last. David K. Chang (Glasgow Royal Infirmary)H-Index: 48
view all 19 authors...
Source
#1Matteo SantoniH-Index: 44
#2Francesco MassariH-Index: 41
Last. Roberto Iacovelli (Agostino Gemelli University Polyclinic)H-Index: 32
view all 21 authors...
BACKGROUND Renal cell carcinoma with sarcomatoid differentiation is a highly aggressive form of kidney cancer. OBJECTIVE We aimed to analyze the outcomes of patients treated with cabozantinib for metastatic renal cell carcinoma with sarcomatoid features. METHODS We retrospectively collected data from 16 worldwide centers. Overall survival and progression-free survival were analyzed using Kaplan-Meier curves. Cox proportional models were used for univariate and multivariate analyses. RESULTS We c...
Source
Source
#1Lorenzo Belluomini (University of Verona)H-Index: 4
#2Valeria Dionisi (University of Verona)
Last. Sara Pilotto (University of Verona)H-Index: 22
view all 11 authors...
Abstract null null Background null : Improvement in radiotherapy techniques and expected outcomes, as well as in understanding the underlying biological mechanisms contributing to its action (immunomodulation in primis), led to the integration of this therapeutical approach in the current management of advanced non-small cell lung cancer (NSCLC), not only in oncogene-driven tumors, but also in non-oncogene addicted NSCLC where the combination of platinum-based chemotherapy plus pembrolizumab rep...
Source
#1Claudio LuchiniH-Index: 31
#2Rita T. LawlorH-Index: 31
Last. Aldo ScarpaH-Index: 99
view all 10 authors...
PURPOSE OF REVIEW Alternative lengthening of telomeres (ALT) is a telomerase-independent mechanism used by some types of malignancies, including pancreatic neuroendocrine tumors, to overcome the issue of telomere shortening, thus supporting tumor growth and cell proliferation. This review is focused on the most important achievements and opportunities deriving from ALT assessment in PanNET onco-pathology, highlighting the most promising fields in which such biomarker could be implemented in clin...
Source
Source